Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methicillin-Resistant Staphylococcus aureus | 6 | 2023 | 80 | 2.660 |
Why?
|
| Staphylococcal Infections | 7 | 2023 | 279 | 2.210 |
Why?
|
| Rotavirus Vaccines | 6 | 2016 | 8 | 1.790 |
Why?
|
| Community-Acquired Infections | 4 | 2023 | 65 | 1.670 |
Why?
|
| Rotavirus Infections | 5 | 2016 | 12 | 1.650 |
Why?
|
| Gastroenteritis | 4 | 2016 | 26 | 1.520 |
Why?
|
| Carrier State | 3 | 2017 | 39 | 1.060 |
Why?
|
| Georgia | 9 | 2023 | 40 | 0.840 |
Why?
|
| Masks | 1 | 2023 | 30 | 0.810 |
Why?
|
| Ambulatory Care | 2 | 2023 | 195 | 0.740 |
Why?
|
| Staphylococcus aureus | 7 | 2023 | 281 | 0.720 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 809 | 0.700 |
Why?
|
| Pandemics | 2 | 2023 | 810 | 0.690 |
Why?
|
| Rotavirus | 3 | 2016 | 11 | 0.680 |
Why?
|
| Medicaid | 4 | 2023 | 248 | 0.660 |
Why?
|
| Staphylococcal Skin Infections | 2 | 2017 | 25 | 0.570 |
Why?
|
| Child | 16 | 2023 | 7323 | 0.570 |
Why?
|
| Soft Tissue Infections | 1 | 2017 | 26 | 0.540 |
Why?
|
| Infant | 12 | 2021 | 3211 | 0.530 |
Why?
|
| Health Status Disparities | 3 | 2023 | 201 | 0.510 |
Why?
|
| Pediatrics | 2 | 2013 | 367 | 0.500 |
Why?
|
| Antibodies, Neutralizing | 3 | 2025 | 124 | 0.490 |
Why?
|
| Vaccination | 2 | 2016 | 284 | 0.480 |
Why?
|
| Electronic Health Records | 1 | 2019 | 365 | 0.470 |
Why?
|
| Antibodies, Viral | 3 | 2025 | 300 | 0.460 |
Why?
|
| Child, Preschool | 10 | 2023 | 3812 | 0.420 |
Why?
|
| Health Personnel | 2 | 2013 | 222 | 0.400 |
Why?
|
| Lead Poisoning | 2 | 2023 | 12 | 0.390 |
Why?
|
| Lead | 2 | 2023 | 28 | 0.390 |
Why?
|
| Information Systems | 1 | 2011 | 30 | 0.380 |
Why?
|
| Shift Work Schedule | 2 | 2021 | 6 | 0.370 |
Why?
|
| Humans | 37 | 2025 | 92175 | 0.350 |
Why?
|
| Methicillin Resistance | 3 | 2007 | 32 | 0.330 |
Why?
|
| Emergency Service, Hospital | 5 | 2023 | 556 | 0.300 |
Why?
|
| Case-Control Studies | 5 | 2017 | 1898 | 0.300 |
Why?
|
| Abscess | 2 | 2017 | 95 | 0.260 |
Why?
|
| Male | 19 | 2025 | 43858 | 0.250 |
Why?
|
| Infant, Newborn | 4 | 2024 | 2513 | 0.250 |
Why?
|
| Female | 19 | 2025 | 47822 | 0.250 |
Why?
|
| Retrospective Studies | 7 | 2024 | 9675 | 0.240 |
Why?
|
| United States | 8 | 2024 | 7338 | 0.240 |
Why?
|
| Hospitals, Pediatric | 2 | 2024 | 127 | 0.230 |
Why?
|
| Syphilis, Congenital | 1 | 2024 | 9 | 0.230 |
Why?
|
| Feces | 2 | 2016 | 349 | 0.230 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 119 | 0.220 |
Why?
|
| Methicillin | 1 | 2023 | 4 | 0.210 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2024 | 122 | 0.210 |
Why?
|
| Prevalence | 4 | 2017 | 1293 | 0.200 |
Why?
|
| Schools | 1 | 2023 | 79 | 0.200 |
Why?
|
| Research Design | 1 | 2025 | 598 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 887 | 0.180 |
Why?
|
| Interleukin-10 | 1 | 2021 | 160 | 0.180 |
Why?
|
| Chlamydia Infections | 1 | 2020 | 32 | 0.170 |
Why?
|
| AIDS Serodiagnosis | 1 | 2000 | 27 | 0.170 |
Why?
|
| Specialization | 1 | 2020 | 69 | 0.160 |
Why?
|
| Spatial Analysis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Mass Screening | 2 | 2021 | 675 | 0.150 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 84 | 0.150 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 1998 | 21 | 0.150 |
Why?
|
| Immunization, Secondary | 3 | 2025 | 35 | 0.140 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 106 | 0.140 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 308 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2019 | 214 | 0.140 |
Why?
|
| Adult | 9 | 2025 | 27494 | 0.140 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 8 | 0.140 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2017 | 18 | 0.140 |
Why?
|
| Clindamycin | 1 | 2017 | 15 | 0.140 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2017 | 150 | 0.140 |
Why?
|
| Asthma | 2 | 2016 | 1002 | 0.140 |
Why?
|
| Circovirus | 1 | 2016 | 5 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2019 | 204 | 0.140 |
Why?
|
| Virus Shedding | 1 | 2016 | 27 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1773 | 0.130 |
Why?
|
| Machine Learning | 2 | 2023 | 292 | 0.130 |
Why?
|
| DNA, Viral | 1 | 2016 | 253 | 0.130 |
Why?
|
| Mediastinal Diseases | 1 | 1996 | 22 | 0.120 |
Why?
|
| Cross Protection | 1 | 2015 | 9 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2016 | 301 | 0.120 |
Why?
|
| Herpesvirus 1, Human | 1 | 1998 | 245 | 0.120 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 79 | 0.120 |
Why?
|
| Vaccines, Synthetic | 2 | 2025 | 58 | 0.120 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2013 | 20 | 0.110 |
Why?
|
| Incidence | 1 | 2019 | 1654 | 0.110 |
Why?
|
| Nasopharynx | 1 | 2004 | 50 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 1 | 2004 | 49 | 0.110 |
Why?
|
| Vaccines, Combined | 2 | 2023 | 5 | 0.110 |
Why?
|
| Southeastern United States | 1 | 2023 | 9 | 0.110 |
Why?
|
| Diarrhea, Infantile | 1 | 2013 | 2 | 0.110 |
Why?
|
| Molecular Typing | 1 | 2013 | 17 | 0.100 |
Why?
|
| Connecticut | 1 | 2011 | 26 | 0.100 |
Why?
|
| Minnesota | 1 | 2011 | 48 | 0.090 |
Why?
|
| Risk Factors | 4 | 2017 | 5697 | 0.090 |
Why?
|
| Vaccines, Attenuated | 3 | 2016 | 53 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2023 | 176 | 0.090 |
Why?
|
| HIV Infections | 1 | 2000 | 893 | 0.090 |
Why?
|
| Pregnancy | 3 | 2024 | 3105 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2023 | 960 | 0.080 |
Why?
|
| Neurons | 1 | 1998 | 1594 | 0.080 |
Why?
|
| Adolescent | 2 | 2019 | 9493 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2728 | 0.070 |
Why?
|
| Hospitalization | 2 | 2023 | 926 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 1863 | 0.070 |
Why?
|
| Small-Area Analysis | 2 | 2016 | 7 | 0.060 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2025 | 44 | 0.060 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2024 | 9 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2019 | 4466 | 0.060 |
Why?
|
| Policy | 1 | 2023 | 39 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2023 | 156 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 610 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2021 | 36 | 0.050 |
Why?
|
| Linear Models | 1 | 2023 | 427 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2021 | 225 | 0.050 |
Why?
|
| Poverty | 1 | 2023 | 189 | 0.050 |
Why?
|
| Middle Aged | 3 | 2025 | 27001 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 146 | 0.050 |
Why?
|
| Young Adult | 1 | 2023 | 6615 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 44 | 0.040 |
Why?
|
| Chlamydia | 1 | 2020 | 2 | 0.040 |
Why?
|
| Chlamydia muridarum | 1 | 2020 | 3 | 0.040 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2020 | 9 | 0.040 |
Why?
|
| Pregnancy, Ectopic | 1 | 2020 | 36 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 301 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2000 | 45 | 0.040 |
Why?
|
| Photoperiod | 1 | 2020 | 73 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1916 | 0.040 |
Why?
|
| Texas | 1 | 2020 | 126 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 438 | 0.040 |
Why?
|
| Gas Gangrene | 1 | 1999 | 1 | 0.040 |
Why?
|
| Probability | 1 | 2000 | 357 | 0.040 |
Why?
|
| Clostridium perfringens | 1 | 1999 | 8 | 0.040 |
Why?
|
| Urban Population | 1 | 2000 | 229 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2000 | 173 | 0.040 |
Why?
|
| Galactosides | 1 | 1998 | 7 | 0.040 |
Why?
|
| Chondroitin ABC Lyase | 1 | 1998 | 7 | 0.040 |
Why?
|
| Polysaccharide-Lyases | 1 | 1998 | 8 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 340 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2021 | 680 | 0.040 |
Why?
|
| Vero Cells | 1 | 1998 | 103 | 0.040 |
Why?
|
| Chick Embryo | 1 | 1998 | 227 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2023 | 2037 | 0.040 |
Why?
|
| Viral Envelope Proteins | 1 | 1998 | 93 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 840 | 0.040 |
Why?
|
| Astrocytes | 1 | 1998 | 143 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 75 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 490 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2000 | 274 | 0.030 |
Why?
|
| Heparin | 1 | 1998 | 185 | 0.030 |
Why?
|
| Epithelium | 1 | 1998 | 324 | 0.030 |
Why?
|
| Drainage | 1 | 2017 | 169 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 1051 | 0.030 |
Why?
|
| Indoles | 1 | 1998 | 306 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2020 | 361 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 172 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 205 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2016 | 57 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1023 | 0.030 |
Why?
|
| Chicago | 1 | 2000 | 1468 | 0.030 |
Why?
|
| Air Pollution | 1 | 2016 | 93 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1998 | 767 | 0.030 |
Why?
|
| Diarrhea | 1 | 2015 | 180 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 903 | 0.030 |
Why?
|
| Utilization Review | 1 | 2013 | 23 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1731 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3356 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1751 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 219 | 0.030 |
Why?
|
| Patient Admission | 1 | 2013 | 116 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 27974 | 0.020 |
Why?
|
| Age Factors | 1 | 2004 | 1904 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 5426 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 12103 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 2677 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 8725 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 299 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1999 | 145 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1998 | 199 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1998 | 247 | 0.010 |
Why?
|
| Pain | 1 | 1999 | 405 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 923 | 0.010 |
Why?
|